Miraqules co-founder and CEO Sabir Hossain always knew he wanted to follow in his father’s footsteps and run his own business. However, he never imagined he would launch a biotech company built around a technology that could have helped his father after a near-tragic accident years earlier left him almost bleeding to death.
The Bengaluru-based company Miraqules developed a nanotechnology in powder form that mimics blood clotting proteins. This blood clotting powder rapidly produces fibrous compounds at room temperature. These compounds have a high volume-to-ratio and can absorb blood quickly when applied.
Hossain explained that the product provides instant feedback. If a person is bleeding, you apply the powder and the bleeding stops. This entire process happens within one or two minutes.
Miraqules is a Top 20 Startup Battlefield finalist and will be presenting this technology on stage at TechCrunch Disrupt 2025, which is happening this week in San Francisco.
Hossain shared that he developed the technology almost by accident. He went to grad school for biomedical engineering and started working in a research lab focused on biomaterials. His job was to mimic the work of a doctorate student, a task at which he admits he was initially quite bad. Her job was to create 3D structures to help in bone tissue growth and bone generation, but every time Hossain synthesized the material, it dismantled.
One day he took the dismantled particles and ground them into a powder. He brought this powder to a group that was working on blood clotting and struggling to mix their solution properly. The powder worked, clotting the whole blood within five to ten seconds. Hossain rushed to his professor, and from there they began to investigate what made it happen. They discovered a completely new process of combining off-the-shelf materials into a nanomaterial that mimics blood clotting proteins.
Hossain then partnered with his childhood friend, Mubeen Midda, and they began working to develop the technology for use outside the lab, operating with as little funding as possible.
Since then, the company has secured 11 patents across seven different countries, including India, the United States, and Israel.
The technology from Miraqules is already being piloted in a trauma care center in India. The company expects to receive its regulatory clearance in India within the next few months. It is also on track to receive clearance from the U.S. Food and Drug Administration in 2026.
Hossain noted that from the beginning, they went directly to the U.S. FDA through a pre-submission process to get feedback on the necessary steps for product approval, which he said helped them a great deal.
The company has reached these significant milestones with less than 700,000 dollars in capital raised, largely from grants.
Miraqules is looking to ramp up deployment and pilot programs heading into next year. It has already received potential interest from 10 different hospital chains in India and the Israeli Defense Forces.